Literature DB >> 14557444

Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis.

Hugo R Boquete1, Patricia G V Sobrado, Hugo L Fideleff, Ana M Sequera, Ana V Giaccio, Martha G Suárez, Gabriela F Ruibal, Mirta Miras.   

Abstract

We critically evaluated the diagnostic value of IGF-I and IGF-binding protein-3 (IGFBP-3) in GH deficiency (GHD) in children and adults using receiver operating characteristic (ROC) plot analysis. Sixty-six children (chronological age, 1.3-15 yr) were studied: 34 GHD and 32 idiopathic short stature (ISS). Ninety-two adults (chronological age, 18-70 yr) were also evaluated: 72 GHD, 34 of childhood onset (AGHD-CO), and 38 of adult onset (AGHD-AO); and 20 healthy volunteers. The SD score (SDS) for IGF-I was calculated from 596 normal subjects (212 children and 384 adults), and the SDS for IGFBP-3 was calculated from 350 normal subjects (212 children and 138 adults). The ROC plot showed that the best IGF-I SDS cut-off line was -1.65 for children [sensitivity (S), 68%; specificity (Sp), 97%, diagnostic efficiency (DEf), 81%], the cut-off line for AGHD was -1.65 for AGHD-CO (S, 91%; Sp, 100%; DEf, 94%), and the cut-off line for AGHD-AO was -1.80 (S, 81%; Sp, 100%; DEf, 88%). For IGFBP-3 SDS, the best cut-off line was -1.80 for children (S, 90%; Sp, 60%; DEf, 78%); it was -1.45 for AGHD-CO (S, 90%; Sp, 75%; DEf, 82%) and -0.90 for AGHD-AO (S, 90%; Sp, 68%; DEf, 77%). An accurate diagnosis was obtained using IGF-I SDS alone in GHD children 65%; ISS, 97%; AGHD-CO, 92%; AGHD-AO, 86%, with IGFBP-3 SDS alone in GHD children 60%; ISS, 90%; AGHD-CO, 75%; AGHD-AO, 68%. Considering both, an accurate diagnosis was obtained in GHD children 60%; ISS, 87%; AGHD-CO, 71%; AGHD-AO, 64%. In conclusion, our findings support the need to use cut-off lines expressed in SDS obtained using an appropriate statistical methodology for better characterization of the various clinical presentations. IGF-I proved to be more useful because of its good diagnostic efficiency and accuracy in both children and adults, whereas IGFBP-3 did not significantly contribute to the diagnosis of GHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557444     DOI: 10.1210/jc.2003-030412

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Assessment of serum IGF-I concentrations in the diagnosis of isolated childhood-onset GH deficiency: a proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED).

Authors:  G Federico; M E Street; M Maghnie; M Caruso-Nicoletti; S Loche; S Bertelloni; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

2.  Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.

Authors:  Gherardo Mazziotti; Mauro Doga; Stefano Frara; Filippo Maffezzoni; Teresa Porcelli; Luigi Cerri; Roberto Maroldi; Andrea Giustina
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

3.  Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment.

Authors:  S Chiloiro; M Mormando; A Bianchi; A Giampietro; D Milardi; C Bima; G Grande; A M Formenti; G Mazziotti; A Pontecorvi; A Giustina; L De Marinis
Journal:  Endocrine       Date:  2017-08-23       Impact factor: 3.633

4.  The insulin-like growth factor system: towards clinical applications.

Authors:  Leon A Bach
Journal:  Clin Biochem Rev       Date:  2004-08

Review 5.  Diagnosis of adult GH deficiency.

Authors:  V Gasco; G Corneli; S Rovere; C Croce; G Beccuti; A Mainolfi; S Grottoli; G Aimaretti; E Ghigo
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 6.  Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis.

Authors:  Yi Shen; Jian Zhang; Yanhong Zhao; Yu Yan; Yanmei Liu; Jin Cai
Journal:  Eur J Pediatr       Date:  2014-09-13       Impact factor: 3.183

7.  Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.

Authors:  Antonio Bianchi; Ferdinando Valentini; Raffaella Iuorio; Maurizio Poggi; Roberto Baldelli; Marina Passeri; Antonella Giampietro; Linda Tartaglione; Sabrina Chiloiro; Marialuisa Appetecchia; Patrizia Gargiulo; Andrea Fabbri; Vincenzo Toscano; Alfredo Pontecorvi; Laura De Marinis
Journal:  J Exp Clin Cancer Res       Date:  2013-06-21

8.  Consensus and discordance in the management of growth hormone-treated patients: results of a knowledge, attitudes, beliefs, and practices survey.

Authors:  Bradley S Miller; Dorothy I Shulman; Alicia Shillington; Qing Harshaw; Darrell M Wilson; David Schwartz; Michael Kappy; Bert Bakker; David Wyatt
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-27

9.  Do IGF-I concentrations better reflect growth hormone (GH) action in children with short stature than the results of GH stimulating tests? Evidence from the simultaneous assessment of thyroid function.

Authors:  Joanna Smyczyńska; Renata Stawerska; Andrzej Lewiński; Maciej Hilczer
Journal:  Thyroid Res       Date:  2011-01-13

Review 10.  Case Report: A Clinical and Genetic Analysis of Childhood Growth Hormone Deficiency With Familial Hypercholesterolemia.

Authors:  Shengmin Yang; Xiaoan Ke; Hanting Liang; Ran Li; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.